HÃ©lÃ¨ne Fe Gleitz

List of Publications by Year
in descending order

15 papers	439 citations	1040056 9 h-index	1058476 14 g-index
16 all docs	16 docs citations	16 times ranked	701 citing authors

#	Article	IF	Citations
1	Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion. Blood Advances, 2022, 6, 1780-1796.	5.2	7
2	Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell, 2021, 28, 637-652.e8.	11.1	92
3	Isolation of human bone marrow stromal cells from bone marrow biopsies for single-cell RNA sequencing. STAR Protocols, 2021, 2, 100538.	1.2	3
4	Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms. Current Opinion in Hematology, 2021, 28, 364-371.	2.5	17
5	Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood, 2020, 136, 2051-2064.	1.4	56
6	Brain targeted stem cell gene therapy provides long-term correction of mucopolysaccharidosis type II. Molecular Genetics and Metabolism, 2019, 126, S31-S32.	1.1	1
7	An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA. Human Gene Therapy, 2019, 30, 1052-1066.	2.7	13
8	Fibrosis driving myofibroblast precursors in MPN and new therapeutic pathways. HemaSphere, 2019, 3, 142-145.	2.7	1
9	Transcriptional Landscape of the Microenvironment in Bone Marrow Fibrosis at Single Cell Level. Blood, 2019, 134, 1675-1675.	1.4	2
10	Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy. Brain, 2018, 141, 99-116.	7.6	64
11	Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis. Journal of Pathology, 2018, 245, 138-146.	4.5	16
12	A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency. Brain, 2018, 141, 2014-2031.	7.6	80
13	Brainâ€targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms. EMBO Molecular Medicine, 2018, 10, .	6.9	66
14	Whole body correction of severe mucopolysaccharidosis type II by lentiviral-mediated stem cell gene therapy with blood-brain barrier-crossing peptides. Molecular Genetics and Metabolism, 2017, 120, S56-S57.	1.1	1
15	Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II. PLoS ONE, 2017, 12, e0172435.	2.5	20